JP2023508491A - 骨髄線維症の治療のための化合物 - Google Patents

骨髄線維症の治療のための化合物 Download PDF

Info

Publication number
JP2023508491A
JP2023508491A JP2022539641A JP2022539641A JP2023508491A JP 2023508491 A JP2023508491 A JP 2023508491A JP 2022539641 A JP2022539641 A JP 2022539641A JP 2022539641 A JP2022539641 A JP 2022539641A JP 2023508491 A JP2023508491 A JP 2023508491A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administered
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539641A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021133866A5 (https=
JP2023508491A5 (https=
Inventor
ジャイルス、フランシス、ジェイ
マザール、アンドリュー
Original Assignee
アクチュエイト セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクチュエイト セラピューティクス、インク． filed Critical アクチュエイト セラピューティクス、インク．
Publication of JP2023508491A publication Critical patent/JP2023508491A/ja
Publication of JPWO2021133866A5 publication Critical patent/JPWO2021133866A5/ja
Publication of JP2023508491A5 publication Critical patent/JP2023508491A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022539641A 2019-12-26 2020-12-23 骨髄線維症の治療のための化合物 Pending JP2023508491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
US62/953,654 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (3)

Publication Number Publication Date
JP2023508491A true JP2023508491A (ja) 2023-03-02
JPWO2021133866A5 JPWO2021133866A5 (https=) 2023-12-26
JP2023508491A5 JP2023508491A5 (https=) 2023-12-26

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539641A Pending JP2023508491A (ja) 2019-12-26 2020-12-23 骨髄線維症の治療のための化合物

Country Status (11)

Country Link
US (1) US20230062278A1 (https=)
EP (1) EP4081213A1 (https=)
JP (1) JP2023508491A (https=)
KR (1) KR20230005808A (https=)
CN (1) CN115697323A (https=)
AU (1) AU2020415440A1 (https=)
BR (1) BR112022012819A2 (https=)
CA (1) CA3166251A1 (https=)
IL (1) IL294369A (https=)
MX (1) MX2022008046A (https=)
WO (1) WO2021133866A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2016537433A (ja) * 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
CN112351819B (zh) * 2018-06-05 2023-11-10 开动疗法公司 治疗恶性淋巴增生性疾病的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2016537433A (ja) * 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEIJER, L.: "Pharmacological inhibitors of glycogen synthase kinase 3", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25(9), JPN6012007715, 2004, pages 471 - 480, ISSN: 0005475048 *

Also Published As

Publication number Publication date
CN115697323A (zh) 2023-02-03
BR112022012819A2 (pt) 2022-09-06
CA3166251A1 (en) 2021-07-01
IL294369A (en) 2022-08-01
MX2022008046A (es) 2022-11-14
WO2021133866A1 (en) 2021-07-01
EP4081213A1 (en) 2022-11-02
US20230062278A1 (en) 2023-03-02
AU2020415440A1 (en) 2022-08-04
KR20230005808A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
JP5612482B2 (ja) 癌の処理のためのγ−セクレターゼインヒビターの使用
UA125216C2 (uk) Комбінована терапія
He et al. MRTX-500 phase 2 trial: sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy
US9937169B2 (en) Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2014254052A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
US20140314673A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
Rui et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis
JP2022502492A (ja) 骨髄増殖性疾患の治療法
Xu et al. Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
Bose et al. New concepts of treatment for patients with myelofibrosis
KR20130085939A (ko) 소세포 폐암의 치료 방법
TW201130830A (en) Combined treatment of pancreatic cancer with gemcitabine and masitinib
Alam et al. Uncoupled nitric oxide synthase activity promotes colorectal cancer progression
JP2023508491A (ja) 骨髄線維症の治療のための化合物
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Pasqualetti et al. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis
AU2010328023A1 (en) Method of treating pancreatic cancer
US20240165113A1 (en) Methods of treatment for leukemia
Tsukumo et al. MTOR and regulation of translation
Golla et al. DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. Cancers 2021, 13, 4889
Schram et al. A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors
Chu Towards the Treatment of Secondarily Mutated Leukemia
WO2025049843A1 (en) Compositions for achieving effective dose levels of mtor inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603